TY - JOUR
T1 - AAAAI Work Group Report
T2 - Trends in Oral Food Challenge Practices Among Allergists in the United States
AU - AAAAI Adverse Reactions to Foods Committee
AU - Greiwe, Justin
AU - Oppenheimer, John
AU - Bird, J. Andrew
AU - Fleischer, David M.
AU - Pongracic, Jacqueline A.
AU - Greenhawt, Matthew
N1 - Funding Information:
Conflicts of interest: J. Greiwe is a consultant for AstraZeneca, advisory boards for AstraZeneca and Sanofi Genzyme, and receives speakers bureau honoraria from AstraZeneca, Regeneron, and Sanofi Genzyme. J. Oppenheimer has received research support from and provided adjudication for AstraZeneca, Abbvie, Sanofi, and Novartis; and is a consultant for GlaxoSmithKline. J. A. Bird reports personal fees from Food Allergy Research and Education; personal fees and nonfinancial support from American College of Allergy, Asthma and Immunology; grants from Nestle Health Sciences; personal fees from Nutricia North America; personal fees from Pharm-Olam International Ltd; personal fees and other from Pfizer Pharmaceuticals; grants, personal fees, and nonfinancial support from Aimmune Therapeutics; personal fees from Prota Therapeutics; personal fees from Allergy Therapeutics, Ltd; grants from NIH-NIAID; grants from Novartis; personal fees from AllerGenis; personal fees from Abbott Nutrition International; and grants and personal fees from DBV Technologies, outside the submitted work. D. M. Fleischer received institutional research funding from DBV Technologies and Aimmune Therapeutics; has served as a consultant for and received personal fees from DBV Technologies, Aimmune Therapeutics, Kaleo Pharmaceutical, INSYS Therapeutics, Abbott, Allergenis, Acquestive, and Nestle; and is a nonpaid member of the Scientific Advisory Council for the National Peanut Board and a nonpaid member of clinical advisory boards for Food Allergy Research and Education and Food Allergy and Anaphylaxis Connectivity Team. J. A. Pongracic has received funding from FARE, DBV Technologies, and Aimmune Therapeutics. M. Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Prota, Glaxo Smith Kline, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters.
Funding Information:
Conflicts of interest: J. Greiwe is a consultant for AstraZeneca, advisory boards for AstraZeneca and Sanofi Genzyme, and receives speakers bureau honoraria from AstraZeneca, Regeneron, and Sanofi Genzyme. J. Oppenheimer has received research support from and provided adjudication for AstraZeneca , Abbvie , Sanofi , and Novartis ; and is a consultant for GlaxoSmithKline. J. A. Bird reports personal fees from Food Allergy Research and Education; personal fees and nonfinancial support from American College of Allergy, Asthma and Immunology; grants from Nestle Health Sciences; personal fees from Nutricia North America; personal fees from Pharm-Olam International Ltd; personal fees and other from Pfizer Pharmaceuticals; grants, personal fees, and nonfinancial support from Aimmune Therapeutics ; personal fees from Prota Therapeutics; personal fees from Allergy Therapeutics, Ltd; grants from NIH-NIAID ; grants from Novartis ; personal fees from AllerGenis; personal fees from Abbott Nutrition International; and grants and personal fees from DBV Technologies , outside the submitted work. D. M. Fleischer received institutional research funding from DBV Technologies and Aimmune Therapeutics ; has served as a consultant for and received personal fees from DBV Technologies, Aimmune Therapeutics, Kaleo Pharmaceutical, INSYS Therapeutics, Abbott, Allergenis, Acquestive, and Nestle; and is a nonpaid member of the Scientific Advisory Council for the National Peanut Board and a nonpaid member of clinical advisory boards for Food Allergy Research and Education and Food Allergy and Anaphylaxis Connectivity Team. J. A. Pongracic has received funding from FARE , DBV Technologies , and Aimmune Therapeutics . M. Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention ; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Prota, Glaxo Smith Kline, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters.
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/11/1
Y1 - 2020/11/1
N2 - The oral food challenge (OFC) is the criterion standard for diagnosing food allergy, but prior studies indicate many allergists may not be using OFCs for various reasons. To better understand current OFC trends, practices, and barriers, the American Academy of Allergy Asthma and Immunology (AAAAI) Adverse Reactions to Foods Committee subcommittee updated a 19-item survey (previously administered in 2009) and sent it to AAAAI and American College of Allergy, Asthma, and Immunology (ACAAI) membership. There were a total of 546 respondents who represented approximately a 10% response rate. Among the 546 respondents, compared with 2009, significantly more providers offer OFCs (95% vs 84.5%), offer >10 OFCs per month (17% vs 5.6%), obtain informed consent (82.2% vs 53.6%), and performed OFCs in fellowship (71% vs 45%) (all P <.001). Fellowship OFC training was limited, with 56% performing <10 OFCs in fellowship and 29% performing none. Although 94% see patients <12 months of age, 35.5% do not offer OFCs for early peanut introduction. Although 79% dedicate a supervising medical provider (MD, NP, PA) and 86% have a written OFC protocol, only 60% had a standardized reaction treatment protocol and 56% prepared emergency medications before OFC. Compared with 2009, there was significant worsening of perceived barriers to performing OFCs, including time (65.6% vs 55%), space (55.3% vs 27.1%), staffing (59.6% vs 44.3%), experience (16.9% vs 11.5%), and hospital proximity (10.9% vs 7.9%), though reimbursement as a barrier improved (45.9% vs 53.7%) (all P <.01). Compared with 2009, although more providers offer OFCs, multiple perceived barriers to performing OFCs have worsened. Hesitancy to challenge infants and emergency preparedness issues are emerging potential concerns.
AB - The oral food challenge (OFC) is the criterion standard for diagnosing food allergy, but prior studies indicate many allergists may not be using OFCs for various reasons. To better understand current OFC trends, practices, and barriers, the American Academy of Allergy Asthma and Immunology (AAAAI) Adverse Reactions to Foods Committee subcommittee updated a 19-item survey (previously administered in 2009) and sent it to AAAAI and American College of Allergy, Asthma, and Immunology (ACAAI) membership. There were a total of 546 respondents who represented approximately a 10% response rate. Among the 546 respondents, compared with 2009, significantly more providers offer OFCs (95% vs 84.5%), offer >10 OFCs per month (17% vs 5.6%), obtain informed consent (82.2% vs 53.6%), and performed OFCs in fellowship (71% vs 45%) (all P <.001). Fellowship OFC training was limited, with 56% performing <10 OFCs in fellowship and 29% performing none. Although 94% see patients <12 months of age, 35.5% do not offer OFCs for early peanut introduction. Although 79% dedicate a supervising medical provider (MD, NP, PA) and 86% have a written OFC protocol, only 60% had a standardized reaction treatment protocol and 56% prepared emergency medications before OFC. Compared with 2009, there was significant worsening of perceived barriers to performing OFCs, including time (65.6% vs 55%), space (55.3% vs 27.1%), staffing (59.6% vs 44.3%), experience (16.9% vs 11.5%), and hospital proximity (10.9% vs 7.9%), though reimbursement as a barrier improved (45.9% vs 53.7%) (all P <.01). Compared with 2009, although more providers offer OFCs, multiple perceived barriers to performing OFCs have worsened. Hesitancy to challenge infants and emergency preparedness issues are emerging potential concerns.
KW - Double-blinded food challenge
KW - Epinephrine
KW - IgE-mediated food allergy
KW - Oral food challenge
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85094558553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094558553&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.07.035
DO - 10.1016/j.jaip.2020.07.035
M3 - Article
C2 - 33161964
AN - SCOPUS:85094558553
SN - 2213-2198
VL - 8
SP - 3348
EP - 3355
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 10
ER -